Twist Bioscience Corp: Form 10-Q for the period ended Jun 30, 2023
Filed with the SEC on Aug 7, 2023 and accepted by EDGAR at Aug 7, 2023, 16:34 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2023-06-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2023-04-01 to 2023-06-30 | $63.7m | us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax |
| Revenue | 9 months2022-10-01 to 2023-06-30 | $178.2m | us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax |
| Cost of revenue | 3 months2023-04-01 to 2023-06-30 | $41.8m | us-gaap:CostOfRevenue |
| Cost of revenue | 9 months2022-10-01 to 2023-06-30 | $113.0m | us-gaap:CostOfRevenue |
| Research and development | 3 months2023-04-01 to 2023-06-30 | $24.5m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months2022-10-01 to 2023-06-30 | $83.1m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months2023-04-01 to 2023-06-30 | $46.1m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 9 months2022-10-01 to 2023-06-30 | $142.3m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2023-04-01 to 2023-06-30 | −$60.8m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2022-10-01 to 2023-06-30 | −$167.0m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2023-04-01 to 2023-06-30 | $1.0k | us-gaap:InterestExpense |
| Interest expense | 9 months2022-10-01 to 2023-06-30 | $4.0k | us-gaap:InterestExpense |
| Income tax | 3 months2023-04-01 to 2023-06-30 | $622.0k | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months2022-10-01 to 2023-06-30 | $1.4m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2023-04-01 to 2023-06-30 | −$57.4m | us-gaap:NetIncomeLoss |
| Net income | 9 months2022-10-01 to 2023-06-30 | −$158.4m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2023-04-01 to 2023-06-30 | −$1.01 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months2022-10-01 to 2023-06-30 | −$2.79 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2023-04-01 to 2023-06-30 | −$1.01 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months2022-10-01 to 2023-06-30 | −$2.79 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2023-04-01 to 2023-06-30 | 57,041,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months2022-10-01 to 2023-06-30 | 56,753,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months2022-10-01 to 2023-06-30 | −$121.8m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months2022-10-01 to 2023-06-30 | $25.4m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2023-06-30 | $307.5m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2023-06-30 | $445.5m | us-gaap:AssetsCurrent |
| Total assets | At period end2023-06-30 | $810.3m | us-gaap:Assets |
| Current liabilities | At period end2023-06-30 | $72.8m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2023-06-30 | $152.8m | us-gaap:Liabilities |
| Shareholders' equity | At period end2023-06-30 | $657.5m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001628280-23-027803. Last ingested by Listed: Oct 27, 2026, 16:07 ET. Listed shows no prices and gives no investment advice.